OPPI welcomes govt’s move to rationalise pricing norms for new drugs

Industry body says the reform will strengthen India's pharmaceutical innovation ecosystem, accelerate access to new therapies, and boost investment in research and development

Organisation of Pharmaceutical Producers of India has welcomed the government's decision to rationalise pricing norms for new drugs, describing the move as a significant reform that will strengthen India's pharmaceutical innovation ecosystem and enhance the country's attractiveness for global investments.

Anil Matai, Director General, Organisation of Pharmaceutical Producers of India (OPPI), said, "The government's decision to rationalise pricing norms for new drugs is a significant and forward-looking reform that strengthens India's resolve to become a global pharma powerhouse. A predictable, transparent and science-driven regulatory environment is critical to accelerating the introduction of new therapies.”

"We welcome this progressive step, which reflects a balanced approach towards enabling a predictable ecosystem that encourages investment while safeguarding patient interests. Continued policy reforms of this nature will further reinforce India's position as a preferred destination for pharmaceutical investments, innovation and healthcare advancement," added Matai.

According to OPPI, the policy change is expected to create a more predictable and transparent regulatory framework, supporting pharmaceutical innovation while facilitating faster patient access to advanced medicines. The industry body also noted that sustained policy reforms will play an important role in strengthening India's position as a global hub for pharmaceutical investment, research, and healthcare innovation.